Tubize-Fin Total Assets
Tubize-Fin total assets. Based on the latest financial reports, Tubize-Fin (TUB) holds total assets worth €1.99 Billion EUR (≈ $2.32 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tubize-Fin market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Tubize-Fin (2000–2025)
Total assets of Tubize-Fin from 2000 to 2025. This chart illustrates how Tubize-Fin's total assets have evolved over time, based on quarterly financial data. See Tubize-Fin (TUB) share price today for real-time trading data and today's change.
Tubize-Fin - Asset Composition Analysis
Tubize-Fin Total Assets Breakdown (December 2025)
Tubize-Fin total assets breakdown as of December 2025. Tubize-Fin's total assets of €1.99 Billion consist of 0.1% current assets and 99.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0.0% |
| Accounts Receivable | €11.40K | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Tubize-Fin's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Tubize-Fin current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tubize-Fin's current assets represent 0.1% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, the same as 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 12.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Tubize-Fin Competitors by Total Assets
Key competitors of Tubize-Fin based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
Tubize-Fin - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 141.54 | 10.33 | 3.28 |
| Quick Ratio | 141.54 | 10.33 | 3.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €49.59 Million | €3.42 Million | €1.61 Million |
Tubize-Fin - Advanced Valuation Insights
This section examines the relationship between Tubize-Fin's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 4.04 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | €1.93 Billion |
| Market Capitalization | $7.82 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tubize-Fin's assets at a significant premium (4.04x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Tubize-Fin's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tubize-Fin (2000–2025)
The table below shows the annual total assets of Tubize-Fin from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.93 Billion ≈ $2.26 Billion |
+0.23% |
| 2024-12-31 | €1.93 Billion ≈ $2.26 Billion |
+0.49% |
| 2023-12-31 | €1.92 Billion ≈ $2.24 Billion |
+4.43% |
| 2022-12-31 | €1.84 Billion ≈ $2.15 Billion |
-43.73% |
| 2021-12-31 | €3.27 Billion ≈ $3.82 Billion |
+15.58% |
| 2020-12-31 | €2.83 Billion ≈ $3.31 Billion |
+2.74% |
| 2019-12-31 | €2.75 Billion ≈ $3.22 Billion |
+10.80% |
| 2018-12-31 | €2.48 Billion ≈ $2.90 Billion |
+7.45% |
| 2017-12-31 | €2.31 Billion ≈ $2.70 Billion |
+3.98% |
| 2016-12-31 | €2.22 Billion ≈ $2.60 Billion |
-1.61% |
| 2015-12-31 | €2.26 Billion ≈ $2.64 Billion |
+23.09% |
| 2014-12-31 | €1.84 Billion ≈ $2.15 Billion |
+1.70% |
| 2013-12-31 | €1.80 Billion ≈ $2.11 Billion |
+1.05% |
| 2012-12-31 | €1.79 Billion ≈ $2.09 Billion |
-4.42% |
| 2011-12-31 | €1.87 Billion ≈ $2.18 Billion |
+4.69% |
| 2010-12-31 | €1.78 Billion ≈ $2.09 Billion |
+3.55% |
| 2009-12-31 | €1.72 Billion ≈ $2.02 Billion |
+8.73% |
| 2008-12-31 | €1.59 Billion ≈ $1.85 Billion |
-5.36% |
| 2007-12-31 | €1.67 Billion ≈ $1.96 Billion |
+4.99% |
| 2006-12-31 | €1.60 Billion ≈ $1.87 Billion |
+56.57% |
| 2005-12-31 | €1.02 Billion ≈ $1.19 Billion |
+42.46% |
| 2004-12-31 | €715.25 Million ≈ $836.21 Million |
-9.58% |
| 2003-12-31 | €791.03 Million ≈ $924.80 Million |
+5.74% |
| 2002-12-31 | €748.11 Million ≈ $874.61 Million |
+15.58% |
| 2001-12-31 | €647.27 Million ≈ $756.73 Million |
+23.22% |
| 2000-12-31 | €525.30 Million ≈ $614.14 Million |
-- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.